Aims: To elucidate if topically applied atorvastatin safely decreases corneal fluorescein staining in dry eyes associated with blepharitis. Methods: Ten dry eye and blepharitis (DEB) patients were enroled in a prospective pilot study. All patients were treated with topical atorvastatin (50 μM) 8 times a day for 4 weeks and allowed to continue with their existing dry eye treatment. The patients were examined weekly for 4 weeks. The primary outcome measure was corneal fluorescein staining. Secondary outcome measures were tear film break-up time (BUT), Schirmer I testing, blepharitis score and bulbar conjunctival injection. The subjective efficacy was evaluated with global symptom and facial analogue scores. Results: An improvement in corneal fluorescein staining in the treated eye by >1 point from baseline to completion of the trial at week 4 was found in 9 of 10 patients (p < 0.01). Topical atorvastatin significantly improved the tear film BUT (p < 0.01), blepharitis score (p < 0.05) and bulbar conjunctival injection (p < 0.05). The global symptom score and facial analogue score also improved (p < 0.05). There were no side effects. Conclusion: Topical atorvastatin is a potential therapy for DEB patients. Larger comparative clinical studies are required to establish the efficacy and safety of topical atorvastatin.

Keywords:
Blepharitis, Dry eye, Topical atorvastatin
1.
Lemp MA: Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes. CLAO J 1995;21:221-232.
2.
Albietz JM: Prevalence of dry eye subtypes in clinical optometry practice. Optom Vis Science 2000;77:357-363.
3.
The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:93-107.
4.
McCulley JP, Shine WE: Changing concepts in the diagnosis and management of blepharitis. Cornea 2000;19:650-658.
5.
Hom MM, Martinson JR, Knapp LL, Paugh JR: Prevalence of meibomian gland dysfunction. Optom Vis Sci 1990;67:710-712.
6.
Lemp MA, Nichols KK: Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf 2009;7(suppl):S1-S14.
7.
Begley CG, Chalmers RL, Mitchell GL, Nichols KK, Caffery B, Simpson T, DuToit R, Portello J, Davis L: Characterization of ocular surface symptoms from optometric practices in North America. Cornea 2001;20:610-618.
8.
Patel VD, Watanabe JH, Strauss JA, Dubey AT: Work productivity loss in patients with dry eye disease: an online survey. Curr Med Res Opin 2011;27:1041-1048.
9.
Tseng SC: Staging of conjunctival squamous metaplasia by impression cytology. Ophthalmology 1985;92:728-733.
10.
Stern ME, Schaumburg CS, Pflugfelder SC: Dry eye as a mucosal autoimmune disease. Int Rev of Immunol. 2013;32:19-41.
11.
Shine WE, McCulley JP: The role of cholesterol in chronic blepharitis. Invest Ophthalmol Vis Sci 1991;2:2272-2280.
12.
Arciniega JC, Uchiyama E, Butovich IA: Disruption and destabilization of meibomian lipid films caused by increasing amounts of ceramides and cholesterol. Invest Ophthalmol Vis Sci 2013;54:1352-1360.
13.
Goto E, Tseng SC: Differentiation of lipid tear deficiency dry eye by kinetic analysis of tear interference images. Arch Ophthalmol 2003;121:173-180.
14.
Acera A, Rocha G, Vecino E, Lema I, Durán JA: Inflammatory markers in the tears of patients with ocular surface disease. Ophthalmic Res 2008;40:315-321.
15.
Wei Y. et al: Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures. Invest Ophthalmol Vis Sci 2013;54:8327-8336.
16.
Kim JH, Chun YS, Kim JC: Clinical and immunological responses in ocular demodecosis J Korean Med Sci 2011;26:1231-1237.
17.
Blanco-Colio LM, Tuñón J, Martín-Ventura JL, Egido J: Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 2003;63:12-23.
18.
Weitz-Schmidt G: Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002;23:482-486.
19.
Niwa S, Totsuka S, Hayashi S: Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996;18:669-675.
20.
Nath N, Giri S, Prasad R, Singh AK, Singh I: Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 2004;172:1273-1286.
21.
Jameel A, Ooi KG, Jeffs NR, Galatowicz G, Lightman SL, Calder VL: Statin modulation of human T cell proliferation, IL-1β and IL-17 production and IFN-γ T cell expression: synergy with conventional immunosuppressive agents. Int J Inflam 2013;2013:434586.
22.
Poon AC, Geerling G, Dart JK, Fraenkel GE, Daniels JT: Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol 2001;85:1188-1197.
23.
Watson SL, Daniels JT, Geerling G, Dart JK: Clinical trials of therapeutic ocular surface medium for moderate to severe dry eye. Cornea 2010;29:1241-1246.
24.
McCulley JP, Dougherty JM, Deneau DG: Classification of chronic blepharitis. Ophthalmology 1982;89:1173-1180.
25.
Raskin EM, Speaker MG, Laibson PR: Blepharitis. Infect Dis Clin North Am 1992;6:777-787.
26.
Lee S-H, Tseng SCG: Rose bengal staining and cytologic characteristics associated with lipid tear deficiency. Am J Ophthalmol 1997;124:736-750.
27.
Pflugfelder SC, Tseng SC, Sanabria O, Kell H, Garcia CG, Felix C, Feuer W, Reis BL: Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea 1998;17:38-56.
28.
Mathers WD, Lane JA, Sutphin JE, Zimmerman MB: Model for ocular tear film function. Cornea 1996;15:110-119.
29.
Marci A, Pflugfelder SC: Correlation of the Schirmer 1 and fluorescein clearance tests with the severity of corneal epithelial and eyelid disease. Arch Ophthalmol 2000;118:1632-1638.
30.
Efron N, Morgan PB, Katsara SS: Validation of grading scales for contact lens complications. Ophthalmic Physiol Opt 2001;21:17-29.
31.
Cornea and Contact Lens Research Unit: CCLRU Grading Scale. Sydney, School of Optometry, University of New South Wales, 1997.
32.
Goto E, Monden Y, Takano Y, Mori A, Shimmura S, Shimazaki J, Tsubota K: Treatment of non-inflamed obstructive meibomian gland dysfunction by an infrared warm compression device. Br J Ophthalmol 2002;86:1403-1407.
33.
Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:108-123.
34.
Tousoulis D, Oikonomou E, Siasos G, et al: Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis 2013; 227:367-372.
35.
Chung YW, Oh TH, Chung SK: The effect of topical cyclosporine 0.05% on dry eye after cataract surgery. Korean J Ophthalmol 2013;27:167-171.
36.
Uchiyama E, Di Pascuale MA, Butovich IA, et al: Impact on ocular surface evaporation of an artificial tear solution containing hydroxypropyl guar. Eye Contact Lens 2008;34:331-334.
37.
Joshi HN, Fakes MG, Serajuddin AT: Differentiation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors by their relative lipohilicity. Pharm Pharmacol Commun 1999;5:269-271.
38.
Schachter M: Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19:117-125.
39.
Watson SL, Coroneo MT: Steroids and the eye. Med Today 2001;2:79-85.
40.
Sall K, Stevenson OD, Mundorf TK, Reis BL: Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107:631-639.
41.
Key JE: A comparative study of eyelid cleaning regimens in chronic blepharitis CLAO J 1996;22:209-212.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.